Monoclonal immunoscintigraphy for detection of metastasis and recurrence of colorectal cancer

Table 1 General parameters in patients examined by all three radiopharmaceuticals

Parameter	Imacis 1	Indimacis 19-9	Oncoscint CR 20	Test
No. of patients	15	18	20	-
CEA (μg/L)				Kruskal-Wallis
Mean (SD)	11.6 (12.2)	8.6 (6.5)	41.2 (60.4)	χ2 = 5.71
Median (rang)	8.9 (1.2-40)	5.9 (3.2-21)	14 (1.3-234)	P = 0.0577
NA	2/15 (13.3%)	8/18 (44.4%)	1/20 (5.0%)
CA 19-9 (U/mL)				Kruskal Wallis
Mean (SD)	27.6 (10.4)	16.2 (4.5)	49.3 (56.5)	χ2 = 10.71
Median (rang)	22.0 (15-42)	14.6 (11.2-27)	24.5 (14-183)	P = 0.0047
NA	6/15 (40.0%)	8/18 (44.4%)	6/20 (30.0%)
US				Fisher’s eact
0	9 (60.0%)	12 (66.7%)	16 (80.0%)	P = 0.5838
1	5 (33.3%)	6 (33.3%)	4 (20.0%)
NA	1 (6.7%)	-	-
CT
0	8 (53.3%)	6 (33.3%)	8 (40.0%)
1	5 (33.3%)	5 (27.8%)	3 (15.0%)	Fisher’s exact
2	-	5 (27.8%)	6 (30.0%)	P = 0.1787
3	-	1 (5.6%)	2 (10.0%)
4	-	-	1 (5.0%)
NA	2 (13.3%)	1 (5.6%)	-
MR
0	2 (13.3%)	-	4 (20.0%)
1	-	-	3 (15.0%)	Fisher’s exact
2	-	-	1 (5%)	P = 0.6
NA	13 (86.67%)		12 (60.0%)
Colonoscopy
0	2 (13.3%)	9 (50.0%)	5 (25.0%)
1	1 (6.67%)	3 (15.0%)	3 (15.0%)	Fisher’s exact
2	3 (20.0%)	2 (11.1%)	2 (10.0%)	P = 0.55942
NA	9 (60.0%)	4 (22.2%)	10 (50.0%)
Rectoscopy
0	5 (33.3%)	8 (44.4%)	5 (25.0%)
1	4 (26.7%)	1 (5.6%)	2 (10.0%)	Fisher’s exact
2	4 (26.7%)	1 (5.6%)	1 (5.0%)	P = 0.42891
NA	2 (13.3%)	8 (44.4%)	12 (60.0%)
Immunoscintgraphy
0	7 (46.7%)	5 (27.8%)	4 (20.0%)
1	2 (13.3%)	5 (27.8%)	3 (15.0%)	Fisher’s exact
2	5 (33.3%)	6 (33.3%)	5 (25.0%)	P = 0.31134
3	1 (6.7%)	2 (11.1%)	7 (35.0%)
NA
SPECT
0	-	2 (11.1%)	3 (15.0%)
1	-	6 (33.0%)	1 (5.0%)
2	-	6 (33.0%)	3 (15.0%)	Fisher’s exact
3	-	2 (11.1%)	7 (35.0%)	P = 0.06137
NA		2 (11.1%)	6 (30.0%)

Type 0- no disease; 1- liver metastases; 2- recurrence; in colonoscopy and rectoscopy: 1- recurrence; 2-stricture and polyposis; 3- liver metastases and recurrence; 4- peritoneal carcinosis. CEA: Carcinoembryonic antigen; NA: Not Analyzed; US: Ultrasound; CT: Computed tomography; MR: Magnetic resonance; SPECT: Single photon emission computed tomography. Oncoscint CR 20: Indium In 111 satumomab pendetide; CA 19-9: Carbohydrate antigen 19-9.

Table 2 Median carcinoembryonic antigen in types of immunoscintigraphy

Type of disease	n	CEA median
0	14	5
1	8	16.25
2	10	9.45
3	9	10
4	1	40

Type 0-no disease; 1-liver metastases; 2-recurrence; 3-liver metastases and recurrence; 4-peritoneal carcinosis. CEA: Carcinoembryonic antigen.

Table 3 Comparison of Cohen‘s κ coefficient for immunoscintigraphy and other diagnostic methods

Method	n	κ
US	52	0.157
CT	50	0.384
MRI	10	0.667
Colonoscopy	31	0.469
Rectoscopy	30	0.655

US: Ultrasound; CT: Computed tomography; MRI: Magnetic resonance imaging.

Table 4 Target/background ratio (mean and SD) in planar and single photon emission computed tomography immunoscintigraphic foci

	Planar	SPECT	n
Indimacis 19-9 mean (SD)
Recurrence	1.2	3.5	1/13
Metastasis	2.03 (0.44)	3.04 (0.8)	13/13
Oncoscint mean (SD)
Recurrence	1.6 (0.24)	2.15 (0.29)	4/5
Metastasis	1.45 (0.26)	1.84 (0.28)	15/15

SPECT: Single photon emission computed tomography.